Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M24,710Revenue (TTM) $M121,546Net Margin (%)1.2Altman Z-Score4.6
Enterprise Value $M27,675EPS (TTM) $4.3Operating Margin %2.0Piotroski F-Score6
P/E(ttm)18.0Beneish M-Score-2.4Pre-tax Margin (%)1.9Higher ROA y-yY
Price/Book3.810-y EBITDA Growth Rate %4.1Quick Ratio0.6Cash flow > EarningsY
Price/Sales0.25-y EBITDA Growth Rate %10.1Current Ratio1.2Lower Leverage y-yN
Price/Free Cash Flow9.4y-y EBITDA Growth Rate %24.0ROA % (ttm)4.4Higher Current Ratio y-yN
Dividend Yield %2.2PEG1.9ROE % (ttm)21.8Less Shares Outstanding y-yY
Payout Ratio %37.0Shares Outstanding M319ROIC % (ttm)17.0Gross Margin Increase y-yN

Gurus Latest Trades with CAH

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CAHArnold Van Den Berg 2016-06-30 Buy 1.01%$73.69 - $87.2
($79.76)
$ 76.90-4%New holding77,330
CAHBarrow, Hanley, Mewhinney & Strauss 2016-06-30 Add0.8%$73.69 - $87.2
($79.76)
$ 76.90-4%Add 114.44%12,520,106
CAHJoel Greenblatt 2016-06-30 Add0.5%$73.69 - $87.2
($79.76)
$ 76.90-4%Add 222.18%768,372
CAHLeucadia National 2016-06-30 Sold Out -0.04%$73.69 - $87.2
($79.76)
$ 76.90-4%Sold Out0
CAHJoel Greenblatt 2016-03-31 Add0.21%$76.16 - $89.68
($81.39)
$ 76.90-6%Add 3980.31%238,494
CAHLeucadia National 2016-03-31 Buy 0.04%$76.16 - $89.68
($81.39)
$ 76.90-6%New holding3,700
CAHBarrow, Hanley, Mewhinney & Strauss 2016-03-31 Reduce$76.16 - $89.68
($81.39)
$ 76.90-6%Reduce -0.13%5,838,381
CAHKeeley Asset Management Corp 2015-12-31 Sold Out -0.25%$77.55 - $90.85
($85.14)
$ 76.90-10%Sold Out0
CAHJoel Greenblatt 2015-12-31 Reduce-0.19%$77.55 - $90.85
($85.14)
$ 76.90-10%Reduce -97.75%5,845
CAHBarrow, Hanley, Mewhinney & Strauss 2015-12-31 Reduce-0.03%$77.55 - $90.85
($85.14)
$ 76.90-10%Reduce -3.49%5,845,797
CAHVanguard Health Care Fund 2015-09-30 Add0.22%$76.72 - $87.02
($83.57)
$ 76.90-8%Add 26.61%6,385,231
CAHJoel Greenblatt 2015-09-30 Add0.04%$76.72 - $87.02
($83.57)
$ 76.90-8%Add 29.25%260,055
CAHBarrow, Hanley, Mewhinney & Strauss 2015-09-30 Reduce-0.04%$76.72 - $87.02
($83.57)
$ 76.90-8%Reduce -5.19%6,057,453
CAHKeeley Asset Management Corp 2015-09-30 Reduce-0.02%$76.72 - $87.02
($83.57)
$ 76.90-8%Reduce -6.59%114,347
CAHJoel Greenblatt 2015-06-30 Reduce-0.02%$83.65 - $91.5
($88.32)
$ 76.90-13%Reduce -14.57%201,203
CAHBarrow, Hanley, Mewhinney & Strauss 2015-06-30 Reduce-0.01%$83.65 - $91.5
($88.32)
$ 76.90-13%Reduce -1.19%6,389,140
CAHKeeley Asset Management Corp 2015-06-30 Reduce$83.65 - $91.5
($88.32)
$ 76.90-13%Reduce -1.65%122,412
CAHBarrow, Hanley, Mewhinney & Strauss 2015-03-31 Reduce-0.03%$79.19 - $91.25
($86.09)
$ 76.90-11%Reduce -4.13%6,465,936
CAHJoel Greenblatt 2015-03-31 Reduce-0.01%$79.19 - $91.25
($86.09)
$ 76.90-11%Reduce -3.23%235,517
CAHKeeley Asset Management Corp 2015-03-31 Add$79.19 - $91.25
($86.09)
$ 76.90-11%Add 0.14%124,467
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CAH is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


CAH: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
LAWS STUART GSVP & Chief Accounting Officer 2016-08-18Sell9,703$82.45-6.73view
MORRISON PATRICIAChief Information Officer 2016-08-18Sell43,959$82.5-6.79view
Giacomin Jon LCEO, Pharmaceutical Segment 2016-08-16Sell47,251$82.77-7.09view
Morford Craig SChief Legal/Compliance Officer 2016-08-11Sell12,697$83.13-7.49view
Barrett George SChairman and CEO 2016-08-10Sell250,000$83.63-8.05view
Casey Donald M Jr.CEO, Medical Segment 2016-08-10Sell59,180$83.59-8view
WATKINS CAROLE SChief HR Officer 2016-05-20Sell84,617$77.33-0.56view
Barrett George SChairman and CEO 2015-11-10Sell54,658$87.73-12.34view
Stephen Falk TEVP, Gen. Counsel & Corp. Sec. 2015-11-06Sell30,085$87.66-12.27view
Barrett George SChairman and CEO 2015-08-20Sell300,000$83.08-7.44view

Quarterly/Annual Reports about CAH:

News about CAH:

Articles On GuruFocus.com
52-Week Company Lows Sep 15 2016 
Scott Black Bought 6 New Stocks in 2nd Quarter Aug 25 2016 
The 3 Worst Performing Dividend Aristocrats This Year Aug 25 2016 
The 10 Best Dividend Aristocrats Aug 15 2016 
Healthcare Dividend Growth Stocks: Part 1 Aug 12 2016 
Van Den Berg's Best Investments of 2nd Quarter Aug 05 2016 
Healthcare Dividend Growth Stocks: Part 1 Aug 04 2016 
Sometimes It Is Good to Buy the Biggest. But Should You Buy the Biggest Health Care Distribution Bus Jul 29 2016 
Arnold Van Den Berg 2nd Quarter: Cuts Back on Gold Miners, Gets More Bullish on Oil Jul 25 2016 
Van Den Berg Made 6 New Buys in 2nd Quarter Jul 24 2016 

More From Other Websites
Cardinal Health to Webcast Discussion of First-Quarter Results for Fiscal Year 2017 on Oct. 31 Sep 28 2016
Cardinal Health to Webcast Discussion of First-Quarter Results for Fiscal Year 2017 on Oct. 31 Sep 28 2016
Smart Access and Best Practices Inform 2017 Medicare Decisions Sep 22 2016
On Cardinal Health, Keep an Eye on $75 Sep 16 2016
Cardinal Health downgraded by Goldman Sep 16 2016
52-Week Company Lows Sep 15 2016
Nasdaq Leads, Dow Stocks Higher As Telecom Sector Heats Up Sep 14 2016
Bulls bet on bounce in Cardinal Health Sep 14 2016
Why It's Time to Buy This Year's Worst-Performing Dividend Aristocrat Stock Sep 14 2016
Startup Insurer Oscar Hires Neurosurgeon as Top Medical Officer Sep 12 2016
Cardinal Health poised to become major Navidea stockholder Sep 07 2016
Navidea Biopharmaceuticals Inc Enters into Letter of Intent with Cardinal Health for the Sale of... Sep 07 2016
Cardinal Health buying Lymphoseek from beleaguered Navidea for up to $310M Sep 06 2016
Navidea stock jumps 76% after company agrees to $80 million Cardinal Health deal Sep 06 2016
Navidea Biopharmaceuticals Enters into Letter of Intent with Cardinal Health for the Sale of... Sep 06 2016
Navidea Biopharmaceuticals Enters into Letter of Intent with Cardinal Health for the Sale of... Sep 06 2016
Cardinal Health commits to recruiting women for leadership Sep 01 2016
Cardinal Health acquisition a big win for Midwestern startup community Aug 31 2016
Fighting Prescription Drug Misuse through Community Programs: Cardinal Health Foundation Announces... Aug 31 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)